Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR-VACC: IDH1-vac in Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas
NCT07888647Phase 2Not yet recruiting
- Sponsor
- German Cancer Research Center
- Start
- Feb 2027
- Primary completion
- Feb 2034
- Countries
- 1
01
Overview
A Phase 2 trial of IDH1R132H dendritic cell vaccine in astrocytoma, sponsored by German Cancer Research Center. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
IDH1R132H dendritic cell vaccine
03
Conditions
astrocytoma
Beyond the preview
Go deeper on NCT07888647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07888647.